About this trial
This is a prospective mixed-design study focused on the long-term management of propionic aciduria (PA) and methylmalonic aciduria (MMA) with N-carbamylglutamate (NCG) maintenance therapy. Treatment characteristics, clinical outcomes, and healthcare utilization data of patients diagnosed PA or MMA treated \>6 months therapy with NCG are collected at baseline, 12 months, 18 months, 36 months and 54 months. Qualitative interviews with adult patients and caregivers are conducted \>6 months after study enrollment to gain a better understanding of the disease burden and the treatment burden of patients and their families.
Eligibility criteria
Qualifiers
Patient has confirmed diagnosis of an organic acidemia (e.g., MMA or PA)
Patient initiated treatment with carglumic acid for long-term management of MMA or PA
Patient has been treated with carglumic acid for a minimum of 6 months
Patient (or caregiver) is able to comply with all prospective study procedures
Disqualifiers
None
Trial design
Treatments tested in this trial
- Carglumic Acid